Alho A, Jaer O, Slungaard U, Holme I
Orthopaedic Service, Ullevaal Hospital, Oslo, Norway.
Clin Rheumatol. 1988 Jun;7(2):208-13. doi: 10.1007/BF02204456.
Two-hundred and fifty-two patients waiting for a total hip replacement for degenerative hip disease were randomized to two groups of nonsteroidal anti-inflammatory medication using piroxicam, 20 mg per day, and naproxen, 750 mg per day, after exclusion for severe dyspepsia or peptic ulcer, asthma, idiosyncracy, dissent, age below 50 years, Harris hip score above 50, or significant contralateral disease. A significant improvement in the pain and daily activity parameters was obtained in both groups. The effect was better in the piroxicam group one month after the commencement of the treatment, and equal in the groups later during the observation period of 2-5 months. We conclude that continuous medication is beneficial in patients with severe osteoarthritis scheduled for operation. However, the side effects of the medication have to be carefully considered and followed up.
252例因退行性髋关节疾病等待全髋关节置换的患者，在排除严重消化不良或消化性溃疡、哮喘、特异反应、不同意、年龄低于50岁、Harris髋关节评分高于50或严重对侧疾病后，被随机分为两组，分别使用每天20毫克吡罗昔康和每天750毫克萘普生这两种非甾体抗炎药。两组患者的疼痛和日常活动参数均有显著改善。治疗开始后1个月，吡罗昔康组的效果更好，在随后2至5个月的观察期内两组效果相当。我们得出结论，对于计划接受手术的重度骨关节炎患者，持续用药是有益的。然而，必须仔细考虑并跟踪药物的副作用。
